1 Min Read
Jan 4 (Reuters) - Bellerophon Therapeutics Inc
* Bellerophon Therapeutics announces FDA acceptance of modifications to INOpulse pulmonary arterial hypertension Phase 3 program Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.